These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 2849974)
21. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035 [TBL] [Abstract][Full Text] [Related]
22. Expression of c-erbB3 protein in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty MK Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984 [TBL] [Abstract][Full Text] [Related]
23. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer. Machotka SV; Garrett CT; Schwartz AM; Callahan R Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995 [TBL] [Abstract][Full Text] [Related]
24. HER-2/neu oncogene protein and prognosis in breast cancer. Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032 [TBL] [Abstract][Full Text] [Related]
25. c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. Uehara T; Kaneko Y; Kanda N; Yamamoto T; Higashi Y; Nomoto C; Izumo T; Takayama S; Sakurai M Jpn J Cancer Res; 1990; 81(6-7):620-4. PubMed ID: 1976118 [TBL] [Abstract][Full Text] [Related]
26. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
27. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Latta EK; Tjan S; Parkes RK; O'Malley FP Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013 [TBL] [Abstract][Full Text] [Related]
28. [Her-2 amplification and p185 expression in invasive breast cancer cells in women]. Titi S Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393 [TBL] [Abstract][Full Text] [Related]
29. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070 [TBL] [Abstract][Full Text] [Related]
30. C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Parkes HC; Lillycrop K; Howell A; Craig RK Br J Cancer; 1990 Jan; 61(1):39-45. PubMed ID: 2153396 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women. Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875 [TBL] [Abstract][Full Text] [Related]
32. Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors? Roux-Dosseto M; Romain S; Dussault N; Martin PM Biomed Pharmacother; 1989; 43(9):641-9. PubMed ID: 2696563 [TBL] [Abstract][Full Text] [Related]
33. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023 [TBL] [Abstract][Full Text] [Related]
34. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Watanabe S; Terada M; Yamamoto H Cancer; 1990 Apr; 65(8):1794-800. PubMed ID: 2156604 [TBL] [Abstract][Full Text] [Related]
35. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
36. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Tsuda H; Iwaya K; Fukutomi T; Hirohashi S Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903 [TBL] [Abstract][Full Text] [Related]
37. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669 [TBL] [Abstract][Full Text] [Related]
39. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Ali IU; Campbell G; Lidereau R; Callahan R Oncogene Res; 1988 Sep; 3(2):139-46. PubMed ID: 3226722 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]